Nafoxidine Hydrochloride
Grundinformationen
- CAS
1847-63-8- Standard-SMILES
COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1.Cl- InChIKey
HJOOGTROABIIIU-UHFFFAOYSA-N- Summenformel
- C29H32ClNO2
- Durchschnittliche Molmasse
- 462 g/mol
- Monoisotopische Masse
- 461,21215694
Überblick
Nafoxidine Hydrochloride is the hydrochloride salt of the partial estrogen antagonist nafoxidine. Nafoxidine competes with endogenous estrogen for binding to specific estrogen receptors. This agent also inhibits angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF); paradoxically, it may enhance angiogenesis in uterine tissue. Nafoxidine also induces oxidative stress, protein kinase C and calcium signaling. (NCI04)
Namen und Bezeichner
- Bevorzugter Name
- Nafoxidine Hydrochloride
- IUPAC
- 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine;hydrochloride
- Englischer Name
- Nafoxidine
- Summenformel
- C29H32ClNO2
- Molmasse
- 462.02288
Namen und Synonyme
NAFOXIDINE HYDROCHLORIDE1847-63-8Nafoxidine HClU-11100AU 11100ANSC-7073511100ASU8WBD61G11-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine hydrochlorideDTXSID30171651NSC70735U-11100
Weitere Namen anzeigen
CP-56CP-5600NafoxidenPNU-0011100Nafoxidene hydrochloride
1-[2-[p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]ethyl]pyrrolidine hydrochlorideRefChem:164409DTXCID6094142U-11,000A1-(2-(4-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)pyrrolidine Hydrochloride439-520-1606-036-9U 11100
Datenbank-Bezeichner
- CAS
1847-63-8- PubChem CID
- 15805
- DTXSID
DTXSID30171651- ChEMBL
CHEMBL2106733- UNII
- SU8WBD61G1
- EC Number
- 439-520-1、606-036-9
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 21,7 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 7
- Schwere Atome
- 33
- Formalladung
- 0
- Komplexität
- 611
Experimentelle und physikochemische Eigenschaften
Endocrine DisruptorsPotential endocrine disrupting compound
Physikochemische Eigenschaften
- Schmelzpunkt
- 165 · 165-168℃
- storage temp.
- room temp
- Löslichkeit
- 2 O: · H2O: ≥8mg/mL
- Aggregatzustand
- powder
- Farbe
- white to tan
- Wasserlöslichkeit
- 2 O: · H2O: ≥8mg/mL
- InChIKey
- HJOOGTROABIIIU-UHFFFAOYSA-N
- SMILES
- Cl.COc1ccc2c(CCC(c3ccccc3)=C2c4ccc(OCCN5CCCC5)cc4)c1
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P302+P352, P317, P318, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
Gefahrenhinweise
Regulatory InformationStatus: Active Update: 10-11-2008 https://echa.europa.eu/registration-dossier/-/registered-dossier/13029
Hazard Classes and Categories
Acute Tox. 3 (100%)
Acute Tox. 4 (100%)
Sicherheitsdaten
- wgk
- 3
- ridadr
- 2811
- RTECS-Nr.
- UY0880000
- risk_code
- 20/21/22-40
- hazard_code
- Xn
- safety_code
- 22-36
- hazard_class
- 6.1(b)
- packing_group
- III
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Acute Tox. 4 DermalAcute Tox. 4 OralCarc. 2
Chemie und Industrie
Pharmakologische Informationen
MeSH Pharmacological Classification
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Anwendungen
VerwendenNafoxidine is a non-steroidal antiestrogenic drug that is structurally related to Tamoxifen (T006000). Nafoxidine is a potent estrogen receptor antagonist that exhibits anti-proliferative properties.
Anbieter36 Anbieter
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
Career Henan Chemica Co+86-0371-86658258 +86-13203830695 · [email protected]
武汉敬康恩生物医药科技有限公司13720134139 086-15871494362 13720134139 · [email protected]
Shanghai Innopharm Industrial Co., Ltd.+86-21-59960785 +86-17701845089 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
欧利希（湖北）医药科技有限公司17316404525 17316404525 · [email protected]
Zugehörige Reaktionen
16
Notizen zur Verbindung
Wird geladen…